Asthma and lower airway diseaseImpulse oscillometry versus spirometry in a long-term study of controller therapy for pediatric asthma
Section snippets
Study population
The study population for the PACT has been described.12 Briefly, children with asthma 6 to less than 14 years of age were screened, characterized, and randomized at 5 clinical centers of the Childhood Asthma Research and Education (CARE) Network funded by the National Heart, Lung, and Blood Institute (NHLBI). The PACT was designed to compare the effectiveness of 3 treatment regimens in achieving asthma control in school-aged children with mild-to-moderate persistent asthma. Inclusion criteria
Demographics/clinical characteristics of study participants
Demographic characteristics were presented by Sorkness et al.12 Of the 285 randomized subjects, 252 completed the study. The 3 treatment groups were well matched, with characteristics at baseline of mild-to-moderate asthma. Of the scheduled visits, 97% were completed. Adherence to study medications was high, as presented in the main outcome article.12 In terms of the primary outcome (asthma control days), fluticasone monotherapy and PACT combination therapy were comparable and superior to
Discussion
Assessment of lung function with IOS was easily accomplished in children with persistent asthma who were 6 to 14 years of age. This study found one IOS parameter (XA) demonstrated continued improvement over a prolonged period of time compared with spirometric variables. As such, IOS might offer a valuable adjunct to spirometry in following the course of subjects enrolled in clinical studies. In terms of biomarkers, a higher level of circulating eosinophils identified subjects more likely to
References (37)
- et al.
Impulse oscillometry provides an effective measure of lung dysfunction in 4-year-old children at risk for persistent asthma
J Allergy Clin Immunol
(2003) Clinical application of forced oscillation
Pulm Pharm Ther
(2001)- et al.
Measurement of respiratory resistance in the emergency department. Feasibility in young children with acute asthma
Chest
(1997) - et al.
Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial
J Allergy Clin Immunol
(2007) - et al.
Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children
J Allergy Clin Immunol
(2003) - et al.
FEV1 is associated with risk of asthma attacks in a pediatric population
J Allergy Clin Immunol
(2001) - et al.
Impulse oscillometry. Reference values in children 100 to 150 cm in height and 3 to 10 years of age
Chest
(2005) - et al.
Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma
J Allergy Clin Immunol
(2006) - et al.
Characterization of within-subject responses to fluticasone and montelukast in childhood asthma
J Allergy Clin Immunol
(2005) - et al.
Airway narrowing measured by spirometry and impulse oscillometry following room temperature and cold temperature exercise
Chest
(2005)
Assessing respiratory function in young children: developmental considerations
J Allergy Clin Immunol
Functional assessment of asthma
The forced oscillation technique in clinical practice: methodology, recommendations and future developments
Eur Respir J
Forced oscillation technique
Comparison of forced oscillometry and forced expirations for measuring dose-related responses to inhaled methacholine in asthmatic children
Bull Eur Physiopathol Respir
Measurement of lung function in awake 2-4-year-old asthmatic children during methacholine challenge and acute asthma: a comparison of the impulse oscillation technique, the interrupter technique, and transcutaneous measurement of oxygen versus whole-body plethysmography
Pediatr Pulmonol
Bronchial responsiveness in asthmatic children aged 3 to 8 years measured by forced pseudo-random noise oscillometry
Bull Eur Physiopathol Respir
Impulse oscillometry: a measure for airway obstruction
Pediatr Pulmonol
Cited by (0)
Supported by grants U10HL064287, 5U10HL064288, 5U10HL064295, 5U10HL064305, and 5U10HL064307 from the National Heart, Lung, and Blood Institute. This study was carried out in part in the General Clinical Research Centers at National Jewish Medical and Research Center (M01 RR00051), Washington University School of Medicine (M01 RR00036), and the University of Wisconsin (MO1 RR03186).
Disclosure of potential conflict of interest: G. L. Larsen is on the Asthma Advisory Board for Genentech and receives grant support from the National Institutes of Health. V. M. Chinchilli receives grant support from the National Heart, Lung, and Blood Institute. R. F. Lemanske is on the speakers' bureau for Merck, is a consultant for GlaxoSmithKline, and receives grant support from the National Heart, Lung, and Blood Institute. F. Martinez is on the Advisory Boards for Merck and MedImmune, receives lecture fees from Merck and Pfizer, and is a consultant for GlaxoSmithKline and Pfizer. S. J. Szefler is a consultant for AstraZeneca, GlaxoSmithKline, Aventis, Genentech, and Merck and receives grant support from the National Institutes of Health; the National Heart, Lung, and Blood Institute; and Ross Pharmaceuticals. R. S. Zeiger is a consultant for Aerocrine, AstraZeneca, Dynavax, Genentech, Merck, Novartis, and GlaxoSmithKline and receives grant support from Sanofi-Aventis, Teva Pharmaceuticals, Merck, AstraZeneca, GlaxoSmithKline, and Genentech. L. B. Bacharier receives honoraria from AstraZeneca, Genentech, GlaxoSmithKline, Merck, and Aerocrine and is on the Advisory Board for Schering-Plough. T. W. Guilbert receives honoraria from GlaxoSmithKline, AstraZeneca, the Peerpoint Medical Education Institute, Merck, Schering-Plough, Genentech/Novartis, and Antidote; receives grant support from Altus Pharmaceuticals, Inspire Pharmaceuticals, the National Institutes of Health, and the National Heart, Lung, and Blood Institute; and is a member of the American Lung Association, American Thoracic Society, and American Academy of Pediatrics. C. A. Sorkness is a consultant and on the speakers' bureau for GlaxoSmithKline and receives grant support from Pharmaxis. The rest of the authors have declared that they have no conflict of interest.
- †
Deceased.